Delivery Order SPE2DB20D3103-SPE2DB25FQ1P5
- Not listed
- The Defense Logistics Agency awarded a $5,270.96 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Cyclophosphamide 1 GM/5 ML in 5 ML vials. This competitive award, utilizing firm fixed price contracting, is scheduled for completion by September 12, 2025, with performance to occur at the contractor's facility in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating it was awarded through full and open competition. This...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $26,197.80 on July 22, 2025, for the supply of Cyclophosphamide 2 GM vials, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 500 mg vials, valued at $1,120.74. The award, issued on August 19, 2025, represents a firm fixed-price delivery order under a competitive, non-set-aside procurement. The pharmaceutical product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $44,261.94 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 2 GM vials. This contract, issued on August 6, 2025, with an ultimate completion date of August 7, 2025, operates under a firm fixed-price arrangement with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- This delivery order, awarded on August 12, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, provides for the supply of Cyclophosphamide 2 GM vials with a ceiling value of $7,341.10 under firm fixed pricing. The award is a non-set-aside contract and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. Performance will be conducted...
- The Defense Logistics Agency awarded a delivery order valued at $1,120.74 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 500 mg vials. The contract, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, operates under firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 500 mg vials under a firm fixed-price contract valued at $1,226.03. This competitively awarded, non-set-aside delivery order was issued on June 30, 2025, with an ultimate completion date of July 1, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Cyclophosphamide is a critical chemotherapy agent used in military and federal healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $2,580.30 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 1 GM vials, with an ultimate completion date of September 5, 2025. This is a firm fixed-price, non-set-aside contract with performance at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is...
- The Defense Logistics Agency awarded a $1,867.90 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Cyclophosphamide 500 mg vials, with an ultimate completion date of September 17, 2025. This firm fixed-price contract represents a non-set-aside award issued through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Cyclophosphamide 50 mg capsules (100 count) valued at $1,942.93. This is a firm fixed-price delivery order with a completion deadline of September 9, 2025, and no set-aside designation was utilized. The work will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ1P5Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $7,619.50 on September 4, 2025, for the supply of Cyclophosphamide 2 GM vials with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. Cyclophosphamide, a chemotherapy and immunosuppressive medication, represents one of the specialized pharmaceutical products within the contractor's extensive portfolio of brand-name and generic drugs, vaccines, and medical supplies delivered through the DLA's Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 9/4/25 |